



# Glycorex Transplantation sponsors a digital symposium on intraoperative Glycosorb® ABO-treatment in pediatric blood group incompatible heart transplantation

Today, March 29, 2022, Glycorex Transplantation is sponsoring a symposium at IPTA 2022 to highlight the unique method developed by Great Ormond Street Hospital (GOSH) in London.

In 2015, the perfusionist team and the transplant team at GOSH in London, introduced a method to incorporate Glycosorb® ABO into the cardiopulmonary bypass system in order to expand the donor pool and facilitate for more children to receive a heart transplant. GOSH has published three articles on the subject<sup>1,2,3</sup>. The results are excellent and have shown significant advantages over the previously used method.

In 2021, BBC wrote about Lucy, a 10-year-old girl, who is thought to be the oldest child in the world to receive a blood group incompatible heart ([link](#)). The GOSH method has also been introduced at other heart transplant centers in Europe.

The International Pediatric Transplant Association (IPTA) is an international transplant congress, attracting participants from over 40 countries.

The symposium "Intraoperative anti-A / B immunoabsorption for ABO-incompatible transplantation" is held digitally / virtually ([link](#)).

In the symposium the ex-vivo model used to create the methodology will be discussed, as well as the first case series of patients transplanted, comparing the outcomes with those undergoing treatment with the previously used method. Finally, a case study will be used to illustrate how intraoperative Glycosorb® ABO is pushing the boundaries of who can undergo a pediatric blood group incompatible heart transplantation.

1. Robertson A, Issitt R, Crook R, Gustafsson K, Eddaoudi A, Tsang V, Burch M; **A novel method for ABO-incompatible heart transplantation** J Heart Lung Transplant. 2018 Apr;37(4):451-457. doi: 10.1016/j.healun.2017.05.006. Epub 2017 May 5.
2. Issitt R, Crook R, Shaw M, Robertson A; **The Great Ormond Street Hospital immunoabsorption method for ABO-incompatible heart transplantation: a practical technique** Perfusion 2021 Jan;36(1):34-37. doi: 10.1177/0267659120926895. Epub 2020 Jun 3.
3. Issitt R, Booth J, Crook R, Robertson A, Molyneux V, Richardson R, Cross N, Shaw M, Tsang V, Muthurangu V, Sebire NJ, Burch M, Fenton M. **Intraoperative anti-A/B immunoabsorption is associated with significantly reduced blood product utilization with similar outcomes in pediatric ABO-incompatible heart transplantation**. J Heart Lung Transplant. 2021 May 29:S1053-2498(21)02325-1.

## Contact

Geert Nygaard, CEO, Glycorex Transplantation AB.  
E-mail: [info@glycorex.se](mailto:info@glycorex.se), phone: 046-286 52 30

## Brief information about the company

Glycosorb® ABO is one of Glycorex Transplantation AB's self-developed proprietary medical devices that is used clinically in four continents to facilitate blood group-compatible transplants, especially in kidney transplants from

related living donors, but the product is also used in liver, heart, lung and stem cell transplantation. The product has so far been used in more than 5,000 kidney transplants. The short-term and long-term results are excellent. The results have been presented in over 60 scientific articles in reputable medical journals. Each kidney transplant has been estimated to save up to SEK 5 million in dialysis costs alone. Each kidney transplant saves about 150 dialysis treatments per year, meaning that the over 5,000 kidney transplants performed after Glycosorb® treatments, can be estimated to save over 700,000 dialysis treatments per year. In addition to Europe, the product is used in India, Canada, Israel, Singapore, Thailand, Mexico and Australia, for example.

The company has also developed a CE-marked medical device for the development of universal blood plasma and are developing products for the specific reduction of autoantibodies in the treatment of autoimmune diseases, as well as products for specific reduction of galectins. The company also develops products for the simultaneous reduction of blood group A/B specific antibodies and HLA antibodies (tissue-specific antibodies). The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis. There are approximately 5 million patients in the EU who have this disease.

Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.